Clovis Oncology (CLVS) Hits New 12-Month Low at $29.76

Clovis Oncology (NASDAQ:CLVS) reached a new 52-week low during trading on Tuesday . The company traded as low as $29.76 and last traded at $30.53, with a volume of 39953 shares traded. The stock had previously closed at $32.69.

A number of equities research analysts recently commented on CLVS shares. Royal Bank of Canada reiterated a “buy” rating and issued a $73.00 target price on shares of Clovis Oncology in a research report on Tuesday, June 12th. ValuEngine upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, June 1st. Cann restated a “hold” rating on shares of Clovis Oncology in a research report on Monday, June 11th. BidaskClub downgraded Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday, June 8th. Finally, Zacks Investment Research downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $73.41.

The company has a quick ratio of 9.21, a current ratio of 10.03 and a debt-to-equity ratio of 1.84. The stock has a market cap of $1.70 billion, a PE ratio of -6.16 and a beta of 1.02.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.56). Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. The company had revenue of $23.76 million for the quarter, compared to analysts’ expectations of $22.44 million. During the same quarter last year, the company earned ($1.29) earnings per share. The company’s revenue for the quarter was up 62.5% on a year-over-year basis. analysts forecast that Clovis Oncology will post -6.77 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Redmile Group LLC purchased a new stake in shares of Clovis Oncology in the second quarter worth approximately $79,964,000. Palo Alto Investors LP raised its holdings in shares of Clovis Oncology by 16.2% in the first quarter. Palo Alto Investors LP now owns 3,955,660 shares of the biopharmaceutical company’s stock worth $208,859,000 after buying an additional 552,879 shares during the period. Summit Trail Advisors LLC raised its holdings in shares of Clovis Oncology by 4,092.7% in the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 243,313 shares during the period. Carmignac Gestion raised its holdings in shares of Clovis Oncology by 14.3% in the first quarter. Carmignac Gestion now owns 1,509,540 shares of the biopharmaceutical company’s stock worth $79,704,000 after buying an additional 188,676 shares during the period. Finally, Emerald Advisers Inc. PA raised its holdings in shares of Clovis Oncology by 71.6% in the second quarter. Emerald Advisers Inc. PA now owns 355,033 shares of the biopharmaceutical company’s stock worth $16,143,000 after buying an additional 148,107 shares during the period.

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Story: Do closed-end mutual funds pay dividends?

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply